A Comparison Study of the Bioavailability of a Capsule Formulation of LGD-6972 to an Oral Solution Formulation

Type 2 Diabetes Mellitus (T2DM) Clinical Trial

Official title:

A Single-Center, Randomized, Open-Label, 2-Period Complete Crossover Study to Compare the Bioavailability of a Capsule Formulation of LGD-6972 to an Oral Solution Formulation in Healthy Adult Subjects

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02672839
• Other study ID #: L6972-03
• Status: Completed
• Phase: Phase 1
• First received: January 27, 2016
• Last updated: May 17, 2016
• Start date: February 2016
• Est. completion date: May 2016

Study information

• Verified date: March 2016
• Source: Ligand Pharmaceuticals
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to compare relative oral bioavailability of a capsule formulation of LGD-6972 to a solution formulation of LGD-6972.

Description:

This is a single center, randomized, open-label, single dose study conducted in a 2-way crossover design.

A total of 8 subjects will be enrolled in the study. The duration of participation for each subject will be approximately 36 days, not including a Screening Period of up to 30 days.

Each treatment period, subjects will be admitted to the study site on Day -1 and observed through the morning of Day 3 (48-hour post-dose assessment). Over 2 treatment periods, subjects will receive each of the following treatments as a single dose orally, under fasting conditions, per the randomization (4 subjects per treatment in each treatment period:

Treatment A - 15 mg of LGD-6972 as capsules

Treatment B - 15 mg LGD-6972 as solution

Serial blood samples will be collected through 48 hours following each dose to determine the concentration of LGD 6972 in plasma. Safety assessments will also occur during this time. Subjects will be discharged from the study site after the 48 hour assessments and return to the study site on Days 4, 7, and 14 for follow up procedures. Subjects will return to the study site for the second treatment period after an additional 7 days. Subjects will be discharged from the study after returning to the study site on Day 14 of the second treatment period.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 12
• Est. completion date: May 2016
• Est. primary completion date: May 2016
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 21 Years to 65 Years

Eligibility

Inclusion Criteria:

1. Healthy, adult man or woman, 21 to 65 years of age. If the subject is a woman, she must be surgically sterile (hysterectomy or bilateral oophorectomy or bilateral tubal ligation), or naturally post menopausal for at least 12 months and with a follicle stimulating hormone (FSH) level in the post-menopausal range (if not taking hormone replacement therapy) to be considered for enrollment

2. Willing and able to provide written informed consent

3. Not diabetic and has a fasting blood glucose between 70 and 105 mg/dL, inclusive

4. In good health with no significant concomitant pathology based on medical history, physical examination, ECG, routine laboratory tests (chemistry, hematology, lipid profile, and urinalysis), and vital signs

5. Has a body mass index (BMI) between 18.5 kg/m2 and 30 kg/m2, inclusive, and must weigh more than 45 kg

6. Male subjects must either have a vasectomy or agree that they and any female partners will use 2 acceptable forms of contraception, one of which must be a condom, until 30 days after the last dose of study drug. Other acceptable forms of contraception include hormonal contraceptives, intrauterine device, Depo Provera®, Norplant® System Implants, bilateral tubal ligation, bilateral oophorectomy, hysterectomy, and contraceptive sponge, foam, or jelly.

Exclusion Criteria:

1. History of drug and/or alcohol abuse within 2 years prior to screening

2. Unwilling to comply with tobacco, nicotine, alcohol, and caffeine restrictions outlined in the protocol

3. Unwilling to comply with restrictions on strenuous exercise as specified in the protocol

4. Has a history of clinically significant cardiovascular, pulmonary, renal, endocrine, hepatic, neurologic, psychiatric, immunologic, hematologic, gastrointestinal (including pancreatitis), or metabolic disease requiring medical treatment or has any medical problems that pose an increased risk during the study or that may compromise the integrity of the study data

5. Has liver transaminase levels (aspartate aminotransferase [AST] or alanine aminotransferase [ALT]) 10% of the upper limit of normal (ULN), or has creatine kinase (CK) levels 2 × ULN at screening or admission to site (Day 1). Abnormal values at screening may be retested once

6. Has a serum triglyceride level 400 mg/dL at screening. If the triglyceride level is between 400 mg/dL and 500 mg/dL, one retest is permitted

7. Recent history of uncontrolled high blood pressure or has systolic blood pressure 90 mmHg or 140 mmHg or diastolic blood pressure 50 mmHg or 90 mmHg at screening. One or more retests of blood pressure within a reasonable period of time are permissible at the discretion of the Investigator

8. Is taking prescription or non-prescription drugs other than those outlined in the protocol

9. Has a positive screening for hepatitis B virus (HBV), hepatitis C virus (HCV), and/or human immunodeficiency virus (HIV)

10. Woman of childbearing potential

11. Lactating or has a positive pregnancy test

12. Has donated 450 mL of blood within 56 days of admission to the investigational site or has donated blood products within 30 days of admission.

Study Design

Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Diabetes Mellitus, Type 2
• Type 2 Diabetes Mellitus (T2DM)

Intervention

Drug:
• LGD-6972 Solution
15 mg of LGD-6972
• LGD-6972 Capsules
15 mg LGD-6972

Locations

Country	Name	City	State
United States	Medpace, Inc	Cincinnati	Ohio

Sponsors (2)

Lead Sponsor	Collaborator
Ligand Pharmaceuticals	Medpace, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Pharmacokinetics Analysis- Area Under the Concentration Curve (AUC)	AUC: ratio: medium test form to reference form	Pre-dose, 1,2,4,6,8,10,12,16,24,36,48,72 hrs, 7 and 14 days post dose	No
Primary	Pharmacokinetics Analysis- Maximum Concentration (Cmax)	Cmax: ratio: medium test form to reference form	Pre-dose, 1,2,4,6,8,10,12,16,24,36,48,72 hrs, 7 and 14 days post dose	No
Secondary	Severity of all Adverse Events graded according to the Common Terminology Criteria for Adverse Events (CTCAE)	The severity of all adverse events will be graded according to the CTCAE version 4.0 from dosing until 14 days post-dose	Day -1, 24, 48, 72hrs, and 7day and 14day post dose	Yes